Paradoxically, however, MHC-II neoantigen presentation on tumor cells can also inhibit antitumor effects, possibly by inducing neoantigen-reactive regulatory CD4+ T cells in the tumor microenvironment (29). The gene discussed is CD4; the disease is neoplasm.